A study conducted in an animal model of pulmonary hypertension (PH) which measured levels of microRNAs (miRNA) — small molecules that seem to inhibit the activity and production of other molecules — may provide a new understanding of disease causes. The report, “Reversal of MicroRNA Dysregulation in an Animal Model of…
News
Researchers at University College London (UCL) and Actelion Pharmaceuticals presented a study investigating the therapeutic effect of macitentan (Opsumit) in a mouse model of pulmonary hypertension associated with systemic scleroderma (SSc). The presentation, titled “Macitentan Responsiveness Supports the Validity of a Murine Model of Pulmonary Hypertension in Scleroderma…
In a large study investigating the impact of sex in systemic sclerosis-associated pulmonary arterial hypertension (SSc-PAH), a team of researchers analyzed a cohort of Canadian patients and found that the male gender is associated with shorter PAH disease duration and increased burden of SSc disease, although it does not independently impact SSc-PAH survival.
Researchers at the Baskent University Faculty of Medicine in Turkey recently provided an overview of the existing literature regarding portopulmonary hypertension (PoPHT) in patients with advanced liver disease and liver transplant candidates. In these patients, pulmonary hypertension is also defined as PoPHT when pulmonary arterial hypertension (PAH) is associated with…
Action Pharmaceuticals recently announced that the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has released a positive opinion on the use of Uptravi (selexipag) for the treatment of patients with a diagnosis of pulmonary arterial hypertension (PAH). Uptravi is an oral IP prostacyclin receptor agonist.
In a new study, researchers used novel cardiovascular magnetic resonance (CMR) tissue phase mapping (TPM) to determine if right ventricular disease in pulmonary hypertension (PH) patients also resulted in abnormal left ventricular functioning, discovering that left ventricular myocardial velocities are significantly abnormal in PH and also constitute independent predictors of clinical…
Increasing numbers of people in the United Kingdom are being treated for pulmonary hypertension, with a 21 percent increase in new referrals over the last five years, representing a jump t0 2,165 from 1,789 between 2010 and 2015, according to results from a national audit published by the Health and Social…
Bellerophon Therapeutics recently announced results from the final analysis of the second part of its Phase 2 clinical trial evaluating INOpulse for the treatment of pulmonary arterial hypertension (PAH), supporting the device’s continued evaluation in an upcoming Phase 3 trial. INOpulse is a proprietary device consisting of a pulsative delivery system…
People with connective tissue disease (CTD) and systemic sclerosis-associated pulmonary arterial hypertension (PAH) who are positive for anti-U1 RNP antibodies have better chances of longer-term survival. The study, “Characteristics and Survival of Anti–U1 RNP Antibody–Positive Patients With Connective Tissue Disease–Associated Pulmonary Arterial Hypertension,” was published in the journal…
The Orlando Health Heart Institute’s Pulmonary Hypertension Program was recently recognized as an accredited comprehensive care center through the Pulmonary Hypertension Association (PHA)’s accreditation program for Pulmonary Hypertension Care Centers (PHCCs). Qualifying PHCCs are either designated as a PHA-accredited Center of Comprehensive Care (CCC) or PHA-accredited Regional Clinical Program (RCP) based on…
A recent Japanese study suggested that it might be more advantageous to combine sildenafil with ambrisentan than with bosentan as a therapy for patients with pulmonary arterial hypertension (PAH). Researchers found that bosentan reduced the concentration of sildenafil in the plasma when the drugs were taken together, while sildenafil combined with ambrisentan…
Don Stevenson, also known as the Pacing Parson, is marking his 80th birthday with a 1,000-mile benefit and awareness walk for the Pulmonary Hypertension Association (PHA), a nonprofit group dedicated to extending and improving the lives of those affected by pulmonary hypertension (PH). The PHA is asking the public to support Stevenson in his efforts.
